A study by the Kenya Medical Research Institute (Kemri) of Kenyan girls aged 15 and 17 showed that one dose of the vaccine was as effective as the current two and three dose regimens.
The survey, carried out between December 2018 and June 2021, included 2,275 girls in Kenya who were randomly assigned to therapy. Of these, 760 received a bivalent vaccine that covered two HPV strains (16/18), which accounts for 70% of the cases.
A total of 758 received a nonavalant vaccine that covered seven HPV strains (16 / 18/31/33/45/52/58), which accounts for 90 percent of the cases, while the remaining 757 girls received a vaccine that protects against meningitis.
After 18 months, the bivalent vaccine was 97, 5 percent effective against HPV 16/18, as was the non-avalent vaccine.
“The non-avalant vaccine was 89 percent effective against HPV 16/18/31/33/45/52/58. Even when women tested positive for one strain of HPV, the vaccine protected them from other strains of the virus, ”the study says.
To be eligible, participants had to be sexually active and no more than five have life partners who are HIV negative and have no history of HPV vaccination.
“This is historical and shows that vaccines save lives,” said Dr senior senior clinical research scientist at the Center for Clinical Research in Kemri .
“This study brings new energy to the elimination of cervical cancer. It gives great hope to women in countries like Kenya, which have a high burden of disease, “she added.
The researchers said one reason for the study is the cervical cancer ward at Kenyatta National Hospital – they want that it’s empty.
Worldwide, cervical cancer kills one woman every two minutes, according to the Director General of the World Health Organization (WHO), Tedros Ghebreyesus. Most of these deaths occur in Africa, which bears 80 percent of the cervical cancer burden.
Cervical cancer is the second most common cancer in women in Kenya after breast cancer. According to the International Agency for Research on Cancer (IARC), there were 5,236 (19.7 percent) new cases of cervical cancer in women of all ages in Kenya in 2020.
Nearly nine out of ten deaths are in countries with low rates and middle-income groups who have little access to early detection of cervical cancer.
More than 100 countries have started using the vaccine as part of WHO routine vaccination schedules.
The WHO strategy for Cervical Cancer Eradication by 2030 calls for 90 percent of girls to be fully vaccinated against HPV by age 15, 70 percent of women with a high-precision test between ages 35 and 45, and 90 percent of women with cervical cancer .
In Kenya, 10-year-old girls receive the HPV vaccine in two doses six months apart free of charge. The vaccine has been offered to girls since 2019.
“These results mark a turning point that can significantly reduce the incidence of HPV-related cervical cancer and make single-dose HPV vaccination valuable and highly effective in interventions Public health areas that are within our reach, “said Prof. Sam Kariuki, Acting General Manager of Kemri.
” The single dose vaccine was highly effective for HPV vaccination and effectiveness after 18 months same as multiple doses, “said Dr. Ruanne Barnabas, principal investigator on the study and professor of global health at the University of Washington.
The single-dose vaccine would simplify logistics and reduce costs.
“I believe that cervical cancer will be eliminated in my life, “said Dr. Maricianah Onono from Kemri. “So let’s do this, a syringe for every woman.”
“A single-dose HPV schedule could reduce the financial and logistical obstacles we are currently facing. Kemri will work closely with the Ministry of Health and researchers to implement these results, ”said Prof. Kariuki.